Want to see TSE:ZEN full AI Analyst Report?
Top Page
Zentek
(ZEN)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.69
▼(-32.45% Downside)
Action:Reiterated
Date:06/29/26
The score is primarily weighed down by weak financial performance (recurring losses, volatile revenue, and ongoing cash burn), with only modest offset from a relatively low-leverage balance sheet. Technicals are mixed—short-term strength but a broader downtrend and negative MACD—while valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Regulatory clearance enabling commercialization
Health Canada clearance for ZenGUARD is a durable de-risking milestone: it validates the product for Canadian deployment, unlocks an immediate order pipeline, and materially improves the firm's ability to convert R&D into recurring sales and distribution deals over the coming months.
Negative Factors
Persistent cash burn
Ongoing negative operating and free cash flow is a structural constraint: it necessitates external funding or dilution, limits reinvestment in commercialization and scaling, and raises execution risk if product revenues don't quickly convert to sustained positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory clearance enabling commercialization
Health Canada clearance for ZenGUARD is a durable de-risking milestone: it validates the product for Canadian deployment, unlocks an immediate order pipeline, and materially improves the firm's ability to convert R&D into recurring sales and distribution deals over the coming months.
Read all positive factors
Zentek (ZEN) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$84.84M
Dividend YieldN/A
Average Volume (3M)66.24K
Price to Earnings (P/E)―
Beta (1Y)1.39
Revenue Growth-80.97%
EPS Growth5.84%
CountryCA
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume86,681
30 Day Avg. Volume66,239
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Zentek Business Overview & Revenue Model
Company Description
Zentek Ltd. (ZEN) is a Canadian technology company specializing in advanced materials and innovative solutions for various industries, including healthcare, energy, and environmental sectors. The company is focused on developing and commercializin...
How the Company Makes Money
null...
Zentek Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
58
Neutral
Cash Flow
21
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 166.05K | 872.50K | 29.82K | 72.86K | 339.67K |
| Gross Profit | -6.29M | 192.49K | -385.06K | -780.48K | -275.04K |
| EBITDA | -10.30M | -9.35M | -11.08M | -13.75M | -11.27M |
| Net Income | -9.77M | -10.04M | -11.70M | -14.41M | -38.69M |
Balance Sheet | |||||
| Total Assets | 15.09M | 18.40M | 22.59M | 33.29M | 37.98M |
| Cash, Cash Equivalents and Short-Term Investments | 1.30M | 121.48K | 3.52M | 10.36M | 26.68M |
| Total Debt | 1.91M | 680.47K | 1.24M | 1.61M | 2.23M |
| Total Liabilities | 5.28M | 3.65M | 2.41M | 2.90M | 3.44M |
| Stockholders Equity | 9.80M | 14.75M | 20.17M | 30.38M | 34.55M |
Cash Flow | |||||
| Free Cash Flow | -5.77M | -6.28M | -8.37M | -15.23M | -11.97M |
| Operating Cash Flow | -5.07M | -6.28M | -8.05M | -12.96M | -7.99M |
| Investing Cash Flow | 1.67M | 358.65K | 1.88M | -2.31M | -7.25M |
| Financing Cash Flow | 4.58M | 2.52M | -665.47K | -1.05M | 38.82M |
Zentek Technical Analysis
Negative
1.02
Price Trends
0.76
Negative
0.76
Negative
0.91
Negative
Market Momentum
>-0.01
Negative
49.35
Neutral
38.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZEN, the sentiment is Negative. The current price of 1.02 is above the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.76, and above the 200-day MA of 0.91, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 38.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ZEN.
Zentek Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | C$160.84M | -47.08 | -0.52% | ― | -8.88% | -179.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$57.80M | -31.98 | ― | ― | -40.80% | 22.49% | |
46 Neutral | C$56.38M | -21.43 | 70.15% | ― | ― | 16.99% | |
44 Neutral | C$84.84M | -7.19 | -61.26% | ― | -80.97% | 5.84% | |
40 Underperform | C$33.74M | -12.81 | -434.25% | ― | ― | 14.18% |
* Healthcare Sector Average
TSE:ZEN
Zentek
0.64
-0.58
-47.54%
TSE:ARCH
Arch Biopartners
0.84
-0.89
-51.45%
TSE:BUX
BioMark Diagnostics
0.55
0.21
61.76%
TSE:MDP
Medexus Pharmaceuticals Inc
5.13
2.33
83.21%
TSE:SONA
Sona Nanotech Inc
0.31
-0.48
-60.76%
Zentek Corporate Events
Business Operations and Strategy
Zentek Orders New PEA to Advance High-Purity Albany Graphite Project
Positive
Apr 9, 2026
Zentek’s Albany Graphite Corp. has retained Micon International to complete a new Preliminary Economic Assessment for the Albany Graphite Project near Hearst, Ontario, with completion targeted for this summer. The study will incorporate upda...
Business Operations and Strategy
Zentek Taps ICP Securities for Algorithmic Market-Making to Boost Liquidity
Positive
Apr 1, 2026
Zentek Ltd., a Canadian IP development company specializing in graphene-enabled and advanced material technologies for clean air, next-generation materials and critical minerals, operates key platforms including Albany Graphite, ZenGUARD™ an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.